Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescence in situ hybridisation and array-based comparative genomic hybridisation

References

• Chiorazzi N, Rai K R, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804–815
   PubMed Web of Science ®Google Scholar
• Hamblin T J. Chronic lymphocytic leukaemia: clinical translations of biological features. Curr Top Microbiol Immunol 2005; 294: 165–185
   PubMed Web of Science ®Google Scholar
• Binet J L, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G, et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 2006; 107: 859–861
   PubMed Web of Science ®Google Scholar
• Rai K R, Sawitsky A, Cronkite E P, Chanana A D, Levy R N, Pasternack B S. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–234
   PubMed Web of Science ®Google Scholar
• Binet J L, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198–206
   PubMed Web of Science ®Google Scholar
• Hamblin T J, Davis Z, Gardiner A, Oscier D G, Stevenson F K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854
   PubMed Web of Science ®Google Scholar
• Damle R N, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S L, et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847
   PubMed Web of Science ®Google Scholar
• Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764–1775
   PubMed Web of Science ®Google Scholar
• Hallek M, Wanders L, Ostwald M, Busch R, Senekowitsch R, Stern S, et al. Serum β(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 1996; 22: 439–447
   PubMed Web of Science ®Google Scholar
• Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916
   PubMed Web of Science ®Google Scholar
• Oscier D G, Wade R, Orchard J, Davis Z, Best G, Morilla A, et al. Prognostic factors in the UK LRF CLL4 trial (abstract). Blood 2006; 108: 299
   Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E, Oscier D, Dyer M J, Bezares R F, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370: 230–239
   PubMed Web of Science ®Google Scholar
• Best O G, Gardiner A C, Davis Z A, Ibbotson R E, Majid A, Dyer M JS, et al. A subset of CLL patients with TP53 abnormalities and mutated VH genes have stable disease (abstract). Leuk Lymphoma 2007; 48(Suppl 1)S80–S81
   PubMed Web of Science ®Google Scholar
• Greshock J, Naylor T L, Margolin A, Diskin S, Cleaver S H, Futreal P A, et al. 1-Mb resolution array-based comparative genomic hybridization using a BAC clone set optimized for cancer gene analysis. Genome Res 2004; 14: 179–187
   PubMed Web of Science ®Google Scholar
• Albertson D G, Pinkel D. Genomic microarrays in human genetic disease and cancer. Hum Mol Genet 2003; 12: R145–R152
   PubMed Web of Science ®Google Scholar
• Natrajan R, Little S E, Sodha N, Reis-Filho J S, Mackay A, Fenwick K, et al. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour. J Pathol 2007; 211: 52–59
   PubMed Web of Science ®Google Scholar
• Vousden K H, Lane D P. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8: 275–283
   PubMed Web of Science ®Google Scholar
• Bentz M, Huck K, du Manoir S, Joos S, Werner C A, Fischer K, et al. Comparative genomic hybridization in chronic B-cell leukemias shows a high incidence of chromosomal gains and losses. Blood 1995; 85: 3610–3618
   PubMed Web of Science ®Google Scholar
• Gonzalez D, Martinez P, Rudenko H, Brito V, Gonzalez M, Hernandez J M, et al. Molecular characterisation of TP53 abnormalities in CLL patients with 17p deletion (abstract). Leuk Lymph 2007; 48(suppl 1)S139
   Google Scholar
• Stankiewicz P, Shaw C J, Dapper J D, Wakui K, Shaffer L G, Withers M, et al. Genome architecture catalyzes nonrecurrent chromosomal rearrangements. Am J Hum Genet 2003; 72: 1101–1116
   PubMed Web of Science ®Google Scholar
• Fink S R, Smoley S A, Stockero K J, Paternoster S F, Thorland E C, Van Dyke D L, et al. Loss of TP53 is due to rearrangements involving chromosome region 17p10 ∼ p12 in chronic lymphocytic leukemia. Cancer Genet Cytogenet 2006; 167: 177–181
   PubMed Web of Science ®Google Scholar
• Callet-Bauchu E, Salles G, Gazzo S, Poncet C, Morel D, Pagès J, et al. Translocations involving the short arm of chromosome 17 in chronic B-lymphoid disorders: frequent occurrence of dicentric rearrangements and possible association with adverse outcome. Leukemia 1999; 13: 460–468
   PubMed Web of Science ®Google Scholar
• Sankar M, Tanaka K, Kumaravel T S, Arif M, Shintani T, Yagi S, et al. Identification of a commonly deleted region at 17p13.3 in leukemia and lymphoma associated with 17p abnormality. Leukemia 1998; 12: 510–516
   PubMed Web of Science ®Google Scholar
• Hoff C, Seranski P, Mollenhauer J, Korn B, Detzel T, Reinhardt R, et al. Physical and transcriptional mapping of the 17p13.3 region that is frequently deleted in human cancer. Genomics 2000; 70: 26–33
   PubMed Web of Science ®Google Scholar
• Goh K O. Chromosomal abnormalities in chronic lymphocytic leukemia. Cancer Genet Cytogenet 1985; 16: 103–107
   PubMed Web of Science ®Google Scholar
• Pfeifer D, Pantic M, Skatulla I, Rawluk J, Kreutz C, Martens U M, et al. Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood 2007; 109: 1202–1210
   PubMed Web of Science ®Google Scholar
• Fernàndez V, Jares P, Salaverria I, Giné E, Beà S, Aymerich M, et al. Gene expression profile and genomic changes in disease progression of early-stage chronic lymphocytic leukemia. Haematologica 2008; 93: 132–136
   PubMed Web of Science ®Google Scholar
• Tompkins V, Hagen J, Zediak V P, Quelle D E. Identification of novel ARF binding proteins by two-hybrid screening. Cell Cycle 2006; 5: 641–646
   Google Scholar
• Lowe S W, Sherr C J. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev 2003; 13: 77–83
   PubMed Web of Science ®Google Scholar
• Eymin B, Leduc C, Coll J L, Brambilla E, Gazzeri S. p14ARF induces G2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice. Oncogene 2003; 22: 1822–1835
   PubMed Web of Science ®Google Scholar
• Perucca P, Cazzalini O, Mortusewicz O, Necchi D, Savio M, Nardo T, et al. Spatiotemporal dynamics of p21CDKN1A protein recruitment to DNA-damage sites and interaction with proliferating cell nuclear antigen. J Cell Sci 2006; 119: 1517–1527
   Google Scholar
• Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia 2007; 21: 2442–2451
   PubMed Web of Science ®Google Scholar
• Lehmann S, Ogawa S, Raynaud S D, Sanada M, Nannya Y, Ticchioni M, et al. Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia. Cancer 2008 15; 112: 1296–1305
   PubMed Web of Science ®Google Scholar
• Satterwhite E, Sonoki T, Willis T G, Harder L, Nowak R, Arriola E L, et al. The BCL11 gene family: involvement of BCL11A in lymphoid malignancies. Blood 2001; 98: 3413–3420
   PubMed Web of Science ®Google Scholar
• Joos S, Menz C K, Wrobel G, Siebert R, Gesk S, Ohl S, et al. Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood 2002; 99: 1381–1387
   PubMed Web of Science ®Google Scholar
• Schwaenen C, Nessling M, Wessendorf S, Salvi T, Wrobel G, Radlwimmer B, et al. Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations. Proc Natl Acad Sci USA 2004; 101: 1039–1044
   PubMed Web of Science ®Google Scholar
• Chevallier P, Penther D, Avet-Loiseau H, Robillard N, Ifrah N, Mahé B, et al. CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol 2002; 116: 142–150
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Sander S, Bullinger L, Benner A, Leupolt E, Winkler D, et al. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 2007; 92: 1242–1245
   PubMed Web of Science ®Google Scholar
• Andritsos L A, Jones J, Lozanski G, Lin T S, Blum K A, Grever M R, et al. Del(17p13.1) in chronic lymphocytic leukemia confers poor prognosis even at low percentage involvement and increases proportionately with increase in clonal involvement (abstract). Blood 2007; 110: 2073
   Web of Science ®Google Scholar
• Zenz T, Häbe S, Denzel T, Winkler D, Döhner H, Stilgenbauer S. How little is too much? p53 inactivation: from laboratory cutoff to biological basis of chemotherapy resistance. Leukemia, [Epub ahead of print]
   Web of Science ®Google Scholar